Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02765737
Other study ID # EFBUR002
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date January 2019

Study information

Verified date November 2020
Source MiMedx Group, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter, prospective, randomized, controlled feasibility trial to determine the safety and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as compared to Control alone for the treatment of second degree burns (partial thickness burns) as assessed by time to healing and scarring


Description:

Multicenter, prospective, randomized, controlled feasibility trial to determine the safety and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as compared to Control alone for the treatment of second degree burns as assessed by time to healing and scarring


Recruitment information / eligibility

Status Terminated
Enrollment 23
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 12 Months to 70 Years
Eligibility Inclusion Criteria: ll patients enrolled must meet all the following criteria: 1. Patient with burn injury that meets all of the following requirements: 1. Occurred within the last 48 hours 2. Wound is thermal in nature 3. Partial-thickness burn (burn extends through the epidermis and may penetrate into the dermis) 4. Total body surface area (TBSA) of burn(s) is 2-20% for all subjects 5. Burn area(s) located on smooth, flat surface 6. 2 burn areas, each with a minimum size of 16cm2 (burn areas may be two separate burns or within one large burn, see Section 9.4.2) 2. Age = 12 months and = 70 years Exclusion Criteria: Subjects meeting any of the following criteria will be excluded: 1. Burns meeting any of the following criteria: 1. Mechanism of injury was electrical, radiation, chemical or frostbite 2. Wound is larger than 200 cm2 3. Clinically infected burn (as judged by the investigator) 4. Previous or planned treatment of the Burn Area(s) with any of the following: - Biological Skin Substitutes (including Apligraf®, Dermagraft®, etc.) 2. Patient criteria that will make patient ineligible for enrollment: 1. Ventilator dependence 2. Active malignant disease or patient is less than 1 year disease-free 3. Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days 4. Auto-immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) 5. Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator 6. Presence of any condition that is likely to compromise healing in the judgment of the Investigator 7. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence) 8. Patient has been on any investigational drug(s) or therapeutic device(s) in the last 30 days or any previous enrollment in this study 3. Allergy or known sensitivity to any of the following: 1. Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate 2. Silver -

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Dehydrated Human Amnion/Chorion Membrane
Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
Device:
Mepilex Ag


Locations

Country Name City State
United States Bruce Cairns Surgery Burn Center Chapel Hill North Carolina
United States St Elizabeth Reg Med Center Lincoln Nebraska
United States Keck School of Medicine Los Angeles California
United States Drexel University Philadelphia Pennsylvania
United States Arizona Burn Center Phoenix Arizona
United States University of San Diego Nedical Center San Diego California

Sponsors (1)

Lead Sponsor Collaborator
MiMedx Group, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Healing Rate 95% epitheliazation as assesses by the investigator 3 weeks
Primary Freedom from Scarring Vancouver Scar Scale: consists of four variables: pliability, vascularity, height (thickness), and pigmentation. Each variable has four to six possible scores. A total score ranges from 0 to 14, whereby a score of 0 reflects normal skin. 3 Months
Secondary Reduction in pain Visual Analog Scale or FLACC Behavioral Pain Assessment Scale:VAS-No pain on left of line, worst pain imaginable on the right of line; FLACC- 0-2, (0 being least uncomfortable to 2 which is very uncomfortable) 3 weeks